Gw pharmaceuticals plc (GWPH)
CashFlow / Yearly
Dec'19Sep'18Sep'17Sep'16
Cash flows from operating activities
Net loss

-9,019

-295,167

-170,459

-91,696

Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange loss

-2,709

-4,917

-9,280

35,750

Share-based compensation

48,030

31,627

15,479

12,661

Depreciation and amortization

9,240

9,290

7,054

5,152

Deferred income taxes

-9,698

-317

-3,770

-2,343

Gain from sale of priority review voucher

104,117

-

-

-

Other

-39

-241

-1,554

-1

Changes in operating assets and liabilities:
Accounts receivable, net

44,623

804

277

735

Inventory

51,125

13,646

-5

-656

Prepaid expenses and other current assets

9,831

-14,489

12,471

11,415

Other assets

-3,888

564

-

-

Accounts payable

805

2,238

3,171

-403

Current tax liabilities

-963

54

57

432

Accrued liabilities

43,110

16,507

1,253

3,397

Other liabilities

-1,914

-733

150

-

Other current liabilities

-

-

-

-80

Long-term liabilities

-

-

-

195

Net cash used in operating activities

-123,469

-231,868

-148,974

-119,928

Cash flows from investing activities
Proceeds from sale of priority review voucher

104,117

-

-

-

Additions to property, plant and equipment

40,386

31,362

19,285

12,192

Additions to intangible assets

2,102

2,042

812

719

Proceeds from disposal of property, plant and equipment

-

517

-

-

Net cash used in investing activities

61,629

-32,887

-20,097

-12,911

Cash flows from financing activities
Proceeds from issuance of ordinary shares, net of issuance costs

-

297,931

-

273,804

Proceeds from exercise of stock options

2,878

621

122

972

Payments on finance leases

389

276

261

-

Payments on build-to-suit financing obligation

-

-

-

21

Payments on capital leases

-

-

-

157

Payments on landlord financing obligation

543

522

1,074

337

Net cash (used in) provided by financing activities

1,946

297,754

-1,213

274,261

Effect of exchange rate changes on cash

5,330

-240

8,993

-13,268

Net decrease in cash and cash equivalents

-54,564

32,759

-161,291

128,154

Supplemental disclosure of cash flow information:
Income taxes paid

10,462

3,726

2,928

1,241

Interest paid

1,087

1,249

1,232

97

Supplemental disclosure of noncash information:
Property and equipment purchases in accounts payable and accrued liabilities

923

322

1,793

3,407